Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 80Breast Neoplasms 39Neoplasms 6Neoplasm Metastasis 4Leiomyoma 2Infertility 2Breast Neoplasms, Male 2Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunction, Physiological 1Sarcopenia 1Salivary Gland Neoplasms 1Recurrence 1Primary Dysautonomias 1Patient Compliance 1Ovarian Neoplasms 1Osteoporosis 1Osteitis Deformans 1Lymphatic Metastasis 1Kidney Diseases 1Hypertension 1Hyperlipidemias 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1Hodgkin Disease 1Hereditary Sensory and Autonomic Neuropathies 1Hemorrhage 1Fallopian Tube Neoplasms 1Castrate Sensitive Prostate Cancer 1Carcinoma, Ovarian Epithelial 1Bulbo-Spinal Atrophy, X-Linked 1Advanced Prostate Cancer 1

Interventions

vistusertib 1ribociclib 1Tamoxifen 1Letrozole 1Goserelin 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Metastatic Breast Cancer × Goserelin × Clear all
NCT02278120 2024-03-12

MONALEESA-7

Novartis

Phase 3 Completed
672 enrolled 16 charts 1 FDA
Breast

Advanced Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡